Press Release: Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

Dow Jones02-03 19:00

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--February 03, 2025-- 

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

 
Fourth quarter 2024 webcast & conference call details 
   Date:         Wednesday, February 19, 2025 
   Time:         5 p.m. ET 
   Webcast:      The live webcast can be accessed at www.exactsciences.com 
   Telephone:    Domestic callers, dial 888-330-2384 
                 International callers, dial +1 240-789-2701 
                 Access code for both domestic and international callers: 
                 4437608 
 

A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard$(R)$ and Oncotype(R) tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250203349082/en/

 
    CONTACT:    Erik Holznecht 

Exact Sciences Corp.

investorrelations@exactsciences.com

608-800-6605

 
 

(END) Dow Jones Newswires

February 03, 2025 06:00 ET (11:00 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment